Blazing New Trails in Rare Disease & CNS Clinical Studies: An Interview with Dr. Mark Opler

 

About this Podcast: 

In this episode, Mark Opler, PhD, MPH, Chief Research Officer at WCG MedAvante-ProPhase sits down with Steve Smith, WCG’s President of Patient Advocacy to discuss the achievements in the field of CNS and rare disease clinical research. Dr. Opler and Steve highlight the unmet need of therapies available for rare disease, the importance of patient enrollment, ensuring efficacy and safety throughout a trial, and how time is of the essence in every study that is conducted.

About the Author

Steve Smith | President, Patient Advocacy, WCG

Steve Smith is a seasoned patient advocate with an extensive career in software, consulting, process transformation, health care systems and patient-focused drug development. He joined WCG as President Patient Advocacy in 2019 inspired by the incredible value to patients embedded in the wide range of WCG solutions that reduce the time and cost of clinical trials.

Visit Website More Content by Steve Smith | President, Patient Advocacy, WCG
Previous Video
Through the Drug Development Looking Glass: Rare Disorders and the Treatment of Pain
Through the Drug Development Looking Glass: Rare Disorders and the Treatment of Pain

Next Post
On the Future of Psychiatric Disorders: Part 1 of WCG’s Transforming CNS Trials Series
On the Future of Psychiatric Disorders: Part 1 of WCG’s Transforming CNS Trials Series

Benchmark your study enrollment versus competitors

Get Benchmark Data